CSIMarket
 
Livento Group Inc   (NUGN)
Other Ticker:  
 
    Sector  Technology    Industry Software & Programming
   Industry Software & Programming
   Sector  Technology
 
Price: $0.0095 $0.00 0.000%
Day's High: $0.01 Week Perf: 5.56 %
Day's Low: $ 0.01 30 Day Perf: -9.52 %
Volume (M): 392 52 Wk High: $ 0.08
Volume (M$): $ 4 52 Wk Avg: $0.03
Open: $0.01 52 Wk Low: $0.01



 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 367
 Employees 8
 Revenues (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) 3
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 7

Livento Group Inc

We were incorporated in the State of Nevada on October 30, 2013 under the name “Bling Marketing, Inc.” Until December 29, 2014, we were a wholesaler of jewelry, principally earrings, rings and pendants (“BMI Business”). We recognized a minimal amount of sales from operations prior to the three months ended September 30, 2014.

NuGene was incorporated in California in December 2006 and formed and funded by our founders, Ali Kharazmi and Mohammed Kharazmi, M.D. The initial focus of the NuGene was to develop and market customized skin care products. As part of that focus, NuGene sought to leverage the working relationships developed by our founders with the plastic surgery community. NuGene directed significant time and resources on developing anti-aging and scar treatment/reduction products.

In 2007 we continued to focus on age defying products utilizing peptide complexes and nano-encapsulation for absorption into the skin. We introduced a limited product line under the NuGene name, and co-branded the products with an affiliated entity, Genetic Institute of Anti Aging, Inc. (“GIAA”), which is also owned by our founders. We utilized the services of a Korean based contract manufacturer to supply our products. This product line (the “GIAA Line”) was based on the use of peptides and did not utilize stem cells. We had very modest sales in 2007, with our sole customer being GIAA, a related party.

“Cosmeceuticals” refer to the combinations of cosmetics and pharmaceuticals that may offer medicinal or drug-like benefits. The term is more of a marketing term rather than a legal term, with the cosmetics industry having adopted the term in the late 1990’s. The US Food and Drug Administration (the “FDA”) does not recognize the term. While drugs are subject to a review and approval process by the FDA, cosmetics and cosmeceuticals are not subject to the same stringent regulatory regime and scrutiny. As such, if a product has drug properties, it must be approved as a drug. However, cosmeceuticals are not subject to this review and approval process.

Cosmeceuticals offer consumers cosmetic-like treatments with active ingredients, which in our view give them pharmaceutical-like efficacy. Driven by aesthetic-consciousness, according to the May 2014 RNCOS research publication entitled, “Global Cosmeceuticals Market Outlook 2018” the global market for cosmeceutical products has reached an estimated size of $35.1 billion in 2013. We believe that this market benefits from the growing segment of a younger generation of consumers as well as baby boomers who want to preserve their youthful looks. In our view the U.S. cosmeceutical market will continue to be favorably influenced by these growing segments of people who want beautiful and younger looking skin while aging.

In our view, age-defying products represent (and will continue to represent) a significant portion of the facial skincare market. In key markets, we believe that the facial skincare market is positioned for significant growth with limited downside risks from the overall condition of the economy. In order to make claims that products can diminish the signs of aging, marketers are constantly looking for new combinations of specialty ingredients. The category of skincare products based on biotechnology such as human stem cell is in our view just beginning to be developed, and therefore we expect that it has significant growth potential. Our goal is to leverage our knowledge in human adult stem cell technology to develop and commercialize advanced anti-aging skincare products for the retail and professional channels. We intend to develop, manufacture, and market cosmetic skin care and hair products to address this significant market opportunity.

Our business plan entails having our NuGene Line of products continue to be sold domestically and internationally through professional channels, including dermatologists, plastic surgeons, medical offices, and day and resort spas. We also expect to directly market our product through television sales-dedicated channels. We plan to promote brand awareness through advertising, our own sales personnel, other marketing and public relations. We will also partially rely upon the name recognition of Kathy Ireland secured under the License Agreement discussed below. We propose to further expand our sales efforts through our branded website (www.nugene.com) and additional online commerce channels.



   Company Address: 17 State Street New York 10004 NY
   Company Phone Number: 432-8241   Stock Exchange / Ticker: NUGN
   NUGN is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
NANX   -6.74%    
• View Complete Report
   



Expensify Inc

Deficit bigger than a year before at EXFY over the October to December 31 2023 fiscal interval

For the October to December 31 2023 fiscal interval company Diminishing Returns have extended of $-0.08 per share compare to $-0.03 a year before and EPS improved from $-0.21 per share from the previous quarter. The revenue decreased in double digits by -17.357 % to $35.93 million from $43.47 million in the corresponding quarter a year before and sequentially revenue increased by 0.31 % from $35.81 million.

Smith Micro Software Inc

Smith Micro Software Inc Reports a Deficit of $-0.08 per Share in Q4 20232.



Smith Micro Software Inc, a Software and Programming company, recently released its financial results for the October to December 31, 2023 timeframe. The report revealed a significant decline in revenue, accompanied by losses in earnings per share. This article aims to interpret these results and explore their potential impact on the company's future.
Revenue Decline and Earnings Losses:
Over the specified timeframe, Smith Micro Software Inc experienced a concerning revenue decline of -19.763% from $11.41 million to $9.15 million, when compared to the corresponding reporting season a year before. Sequentially, revenue deteriorated by -12.623% from $10.47 million. In contrast, the Software and Programming sector, excluding Smith Micro, witnessed a revenue growth of 9.00% during the same period.
Furthermore, the company reported a net deficit of $-6.711 million for the October to December 31, 2023 timeframe, as opposed to a deficit of $-7.972 million in the corresponding reporting season a year ago. Additionally, the company noted a net loss of $-24.40 million for the fiscal year 2023, with revenue totaling $40.30 million, reflecting a decline of -16.92% compared to the previous fiscal year.

Rapid7 Inc

Company's Stellar Performance Shines Throughout Fourth Quarter of 2023 Earnings Season

Rapid7 Inc Reports Positive Financial Results for Fiscal Year 2023
BOSTON, Feb. 07, 2024 - Rapid7, Inc. (Nasdaq: RPD), a leading provider of extended risk and threat detection solutions, has announced its financial results for the fourth quarter and full-year 2023. The company exhibited significant growth, with impressive increases in revenue and income per share.
For the fiscal period ending December 31, 2023, Rapid7 Inc reported a notable turnaround in income, displaying Income per Share of $0.31 compared to a loss of $0.18 per share the previous year. The company's EPS turned positive from a loss of $1.25 per share in the prior financial reporting period. Moreover, revenue increased by 11.406% to $205.52 million from $184.48 million in the comparable financial reporting period a year ago. Sequentially, revenue surged by 3.792% from $198.01 million.

Procore Technologies Inc

Procore Technologies Inc achieves Marvelous Top-line improvement in Q4 2023

Procore Technologies Inc, a leading global provider of construction management software, has announced impressive financial results for the fourth quarter and full year ended December 31, 2023. The company reported a decrease in loss per share, with a significant improvement from $-0.49 per share to $-0.20 per share compared to a year ago. Additionally, income per share saw an improvement from $-0.31 per share in the preceding reporting season.
One of the most notable highlights of Procore's financial performance was the rapid revenue growth, with an increase of 28.683% to $260.01 million from $202.05 million in the same reporting season a year ago. Sequentially, revenue also surged by 4.934% from $247.78 million. This strong revenue growth is a positive indicator of the company's increasing demand in the market.

Teradata Corporation

Teradata Corporation Reports Revenue Growth in Fourth Quarter of 2023, But Faces Challenges Ahead



Teradata Corporation, a software and programming company, recently released its financial results for the fourth quarter of 2023. While some significant improvements were witnessed, there were areas of concern that need to be addressed in order to drive future growth and enhance investor confidence.
Revenue Growth:
Teradata Corporation experienced an 8.294% increase in revenue, reaching $457.00 million compared to the $422.00 million reported in the same quarter the previous year. Sequentially, the revenue advanced by 4.338% from $438.00 million, highlighting a positive growth trend.






 

Livento Group Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com